Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular-targeted photodynamic therapy using padeliporfin in localized prostate cancer
2009-012809-19Phase 2Active
- Sponsor
- Steba Biotech
- Start
- May 2009
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of padeliporfin VTP in prostate cancer (PCa), sponsored by Steba Biotech. Primary endpoint: Primary efficacy: negative biopsy in treated lobes at 6 months. Started May 2009; status: active.
02
Drugs
padeliporfin VTP
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-012809-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012809-19.